ALK+ non-small cell lung cancer is a rare form of lung cancer affecting around 5% of NSCLC patients. 1 The advent of novel ALK inhibitors has helped significantly improve patient outcomes; however, a lot still remains to be done to address issues, such as treatment resistance and treatment-associated adverse events. What is your approach to managing ALK+ NSCLC? How do you treat any adverse events? Take this 2-minute survey to help us better understand your insights into the treatment of this disease. ##Reference## 1.Jazieh AR, Gaafar R, Errihani H, Jaafar H, Al Dayel F, Bahnassy AA, El Kadi H, Abdallah MM, Zaatari G.
Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer in the Middle East and North Africa. JCO Glob Oncol. 2021 Sep;7:1556-1563. doi: 10.1200/GO.21.00067. PMID: 34788123; PMCID: PMC8613346.## PP-UNP-IND-0184 Date -…
